Cardiorenal links in systemic amyloidosis

Rameev V.V.; Kozlovskaia L.V.; Zhdanova E.A.; Gudkova K.V.

doi:https://doi.org/

Rameev V.V.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Zhdanova E.A.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Gudkova K.V.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Cardiorenal links in systemic amyloidosis

Authors:

Rameev V.V., Kozlovskaia L.V., Zhdanova E.A., Gudkova K.V.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 51‑59

Read: 2563 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rameev VV, Kozlovskaia LV, Zhdanova EA, Gudkova KV. Cardiorenal links in systemic amyloidosis. Therapeutic Archive. 2013;85(6):51‑59. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper gives current general data on the structure of amyloid fibril and the principles in the classification of amyloidosis, information on the clinical course of cardiac and renal involvements in systemic AL and AA amyloidosis, and that on diagnostic and prognostic criteria and the specific features of cardiorenal links. The authors draw the conclusion that the identification of acute and chronic cardiorenal links is of practical value for systemic amyloidosis. Cardiorenal and renocardiac syndromes are not always differentiated clearly in the systemacy of involvement.

Keywords:

and ATTR amyloidosis

cardiorenal syndrome

renal amyloidosis

cardiac amyloidosis

Authors:

Rameev V.V.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Zhdanova E.A.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Gudkova K.V.

Kafedra terapii i profzabolevaniĭ MPF, Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Close metadata

References:

Vinogradova O.M. Pervichnyi i geneticheskie varianty amilodoza. M 1980; 224.
Pennell D.J., Maceira A.M. Magnetic Resonance Imaging in Cardiac Amyloidosis. J Am Coll Cardiol Img 2009; 2: 1378-1380.
Cueto-Garcia L., Tajik A.J., Kyle R.A. et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc1984; 59 (9): 589-597.
Shah K., Inoue Y., Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006; 166 (17): 1805-1813.
Klein A.L., Hatle L.K., Taliercio C.P. et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis J Am Coll Cardiol 1990; 16: 1135-1141.
Demir M., Paydas S., Cayli M. et al. Tissue Doppler is a more reliable method in early detection of cardiac dysfunction in patients with AA amyloidosis. Ren Fail 2005; 27: 415-420.
Klein A.L., Hatle L.K., Taliercio C.P. et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991; 83: 808-816.
Smedema J.-P., James R. Tissue Doppler imaging and contrast-enhanced cardiac magnetic resonance in primary cardiac amyloidosis. Eur J Echocardiogr 2009; 10: 984-986.
Koyama J., Ray-Sequin P.A., Falk R.H. Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients With AL (Primary) Cardiac Amyloidosis. Circulation 2003; 107: 2446-2452.
Takemura G., Takatsu Y., Doyama K. et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998; 31: 754-765.
Rosenzweig M., Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. Creative Commons Attribution License, 2011.
Siqueira-Filho A.G., Cunha C.L., Tajik A.J. et al. M-mode and twodimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63: 188-196.
Dubrey S.W., Cha K., Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157.
Ng B., Connors L.H., Davidoff R. et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165: 1425-1429.
Perugini E., Rapezzi C., Piva T. et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92: 343-349.
Rapezzi C., Merlini G., Quarta C.C. et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120: 1203-1212.